Document Detail

Performance of diadochokinetic movements in schizophrenic patients.
MedLine Citation:
PMID:  15987669     Owner:  NLM     Status:  MEDLINE    
Motor deficits are common and disabling symptoms in schizophrenic patients, which have enormous impact on the long-term outcome of the disease by affecting work performance and daily functioning. They are attributed to the disorder itself, as well as to treatment with dopamine-blocking antipsychotics. This study assessed the kinematic parameters of motor performance of a diadochokinetic hand movement in 20 drug-naïve, 20 conventionally treated (haloperidol or fluphenazine), and 20 atypically treated (olanzapine) patients, as well as in 20 healthy controls using a three-dimensional ultrasonic movement analysis system. It also tested differences in motor enhancement as induced by an attentional strategy and in dexterity advantages of motor performance for the dominant hand between the four study groups. Amplitude and peak velocity of diadochokinetic hand movements were significantly reduced in all patient groups compared to the controls, while frequency of the repetitive movement remained unaffected. The reduction was most pronounced in the conventionally treated patients. In addition, movement automation was impaired, primarily under conventional antipsychotic treatment. The study also revealed weaker effects of an attentional enhancing strategy on the movement amplitude in atypically and conventionally treated patients compared to both controls and drug-naïve patients. Alterations of dexterity could not be detected either in the drug-naïve or in the treated patients. The results indicate that patients with schizophrenia suffer from a specific primary motor deficit in diadochokinesia with reduction of amplitude and peak velocity. This deficit is significantly worsened by conventional antipsychotic treatment. Antipsychotic treatment additionally reduces the enhancing effect of an attentional strategy on motor performance.
Albert Putzhammer; Maria Perfahl; Liane Pfeiff; Bernd Ibach; Monika Johann; Ute Zitzelsberger; Goeran Hajak
Related Documents :
24384859 - Detection of intracardiac masses in patients with coronary artery disease using cardiac...
6108989 - Activity of erythrocyte na,k-atpase in manic patients.
12639169 - Combination risperidone and ssri-induced serotonin syndrome.
21745599 - Biochemical parameters to assess choroid plexus dysfunction in kearns-sayre syndrome pa...
2818139 - Hippocampal pathologic findings in schizophrenia. a morphometric study.
6691489 - Clinical correlates of lateral ventricular enlargement in bipolar affective disorder.
11713119 - Relationship between craniofacial abnormalities and sleep-disordered breathing in marfa...
12892239 - Nervous system involvement by pancreatic cancer.
12600439 - Fundoplication improves disordered esophageal motility.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article     Date:  2005-06-28
Journal Detail:
Title:  Schizophrenia research     Volume:  79     ISSN:  0920-9964     ISO Abbreviation:  Schizophr. Res.     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2005-10-24     Completed Date:  2006-02-14     Revised Date:  2010-09-02    
Medline Journal Info:
Nlm Unique ID:  8804207     Medline TA:  Schizophr Res     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  271-80     Citation Subset:  IM    
Movement Disorders Unit, Department of Psychiatry, University of Regensburg, Regensburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analysis of Variance
Antipsychotic Agents / blood,  therapeutic use
Case-Control Studies
Dose-Response Relationship, Drug
Dyskinesia, Drug-Induced / physiopathology*
Fluphenazine / therapeutic use
Functional Laterality / physiology
Haloperidol / therapeutic use
Hand / physiopathology
Movement / drug effects,  physiology
Psychiatric Status Rating Scales / statistics & numerical data
Psychomotor Disorders / drug therapy,  etiology*
Psychomotor Performance / drug effects,  physiology
Retrospective Studies
Schizophrenia / blood,  complications*,  drug therapy
Schizophrenic Psychology*
Signal Processing, Computer-Assisted
Reg. No./Substance:
0/Antipsychotic Agents; 52-86-8/Haloperidol; 69-23-8/Fluphenazine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Genetic characterization of the mitochondrial DNA from Lepeophtheirus salmonis (Crustacea; Copepoda)...
Next Document:  The neural correlates of understanding the other's distress: a positron emission tomography investig...